Nasdaq
Allarity Therapeutics Regains Compliance With Nasdaq
According to the firm, it was able to meet the Nasdaq listing requirement of having a minimum stockholders' equity of at least $2.5 million.
In Brief This Week: Lexeo Therapeutics, GeneVentiv Therapeutics, Allarity Therapeutics
News items for the week of April 15, 2024.
Allarity Therapeutics 'Retools' Pipeline to Focus on Stenoparib, Deprioritizes Ixempra, Dovitinib
The firm is shifting resources so it can quickly move the PARP/tankyrase inhibitor toward regulatory approval in advanced, biomarker-selected ovarian cancer.
Cero Therapeutics to Go Public Through SPAC Merger
The firm's candidates, including the autologous CER T-cell therapy CER-1236, are engineered to engage the innate and adaptive immune system to treat multiple cancers.
Achilles Therapeutics Receives Nasdaq Noncompliance Notice
The firm is not in compliance with the $1.00 minimum bid price requirement and has 180 days to regain compliance.
Feb 14, 2022
Varian Bio to Go Public Through SPAC Deal With SPK
Oct 8, 2021